The aim of the present study was to determine, retrospectively, whether the immunohistochemical expression of two biologic markers of aggressivity, P-glycoprotein (P-gp) and PCNA/cyclin (PCNA), could be related to response to chemotherapy and prognosis in locally advanced breast cancer.
Methods
PC 10 Mab was used to determine the proliferation index (PCNA) and C-219 Mab to determine P-gp in 25 locally advanced breast carcinomas subjected to preoperative chemotherapy with MDR-related drugs.
Results
P-gp and PCNA were expressed in 76 % and 100 % of the tumors, respectively. No case of high P-gp expression was associated with good chemosensitivity, and all P-gp-negative cases showed the best chemotherapeutic response. P-gp and PCNA were both highly expressed in patients who developed local-regional or distant metastases. No recurrence was associated with a negative or low P-gp score.
Conclusions
Statistical analysis showed that high P-gp expression was related to a poor response to chemotherapy and a short disease-free survival. A high PCNA score was not found to be significant for predicting chemosensitivity or survival.
BattersbyS., AndersonT.J.: Correlation of proliferative activity in breast tissue using PCNA/cyclin.Hum. Pathol., 21: 781, 1990.
2.
Bech-HansenN.T., TillJ.E., LingV.: Pleiotropic phenotype of cholchicine-resistant CHO cells: cross resistance and collateral sensitivity.J. Cell. Physiol., 88: 23–32, 1976.
3.
BlackM.M., SpeerF.D.: Nuclear structure in cancer tissues.Surg. Gynecol. Obstet., 105: 97–102, 1957.
4.
BottiG., De MatteisA., ChiappettaG., D'AiutoG., EspositoG., PiconeA.: Mammary carcinoma. A multiparametric (MDR-P-glycoprotein expression, regional node status, tumor cell kinetics and receptor status) and immunohistochemical study.J. Nucl. Med. All. Sci., 34: 221–223, 1990.
5.
BravoR., FrankR., BlundellP.A., MacDonaldB.H.: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.Nature, 326: 515–517, 1987.
6.
BravoR., MacDonald-BravoH.: Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.J. Cell. Biol., 105: 1549–1554, 1987.
7.
ChiappettaG., BevilacquaA.M., PiconeA., RiccioG., BottiG.: Assessment of multidrug resistance (MDR) by immunohistochemistry in breast carcinoma. Correlation with tumor size and regional node status.J. Nucl. Med. Allied Sci., 34: 217–219, 1990.
8.
ColtreràH.C., GownA.M.: PCNA-cyclin expression and BrdU uptake define different subpopulations in different cell lines.J. Histochem. Cytochem., 39: 23–30, 1991.
9.
DixonW.J.: BMDP statistical software.University of California Press, Berkeley, CA, 1985.
10.
GarciaR.L., ColtreraM.D., GownA.: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis.Am. J. Pathol., 134: 733–739, 1989.
11.
HallP.A., LevisonD.A., WoodsA.L., YuC.C.W., KellockD.B., WatkinsJ.A., BarnesD.M., GilletC.E., CamplejohnR., DoverR., WaseemN.H., LaneD.P.: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.J. Pathol., 162: 285–294, 1990.
12.
HamadaH., TsuruoT.: Functional role for the 170- to 180-kDA glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.Proc. Natl. Acad. Sci., 83: 7785–7789, 1986.
13.
HitchinsR.N., HarmanD.H., DaveyR.A., BellD.R.: Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues.Eur. J. Cancer. Clin. Oncol., 24: 449–454, 1988.
MorrisG.F., MathewsM.B.: Regulation of proliferating cell nuclear antigen during the cell cycle.J. Biol. Chem., 26: 13856–13864, 1989.
16.
RoJ., SahinA., RoJ.Y., FritscheH., HortobagiG., BlickM.: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.Hum. Pathol., 21: 787–791, 1990.
17.
SchneiderJ., BakM., EfferthT., KaufmanM., MatternJ., VolmM.: P-glycoprotein expression in treated and untreated human breast cancer.Br. J. Cancer., 60: 815–818, 1989.
18.
SicikB.I., BrophyN.A., BerryJ.M., MarieJ.P., EhsanM.N., TsuruoT., RoninsonI.B., SmithS.D.: Multidrug resistance gene expression in ovarian and breast cancers, leukemias, and lymphomas (Meeting abstract). Sixth NCI-EORTC Symp on New Drugs in Cancer Therapy. March 7-10, 1989, Amsterdam, A307, 1989.
19.
TravaliS., KuD.H., RizzoM.G., OttavioL., BasergaR., CalabrettaB.: Structure of the human gene for the proliferating cell nuclear antigen.J. Biol. Chem., 264: 7466–7472, 1989.
20.
Van der ValkP., Van KalkenC.K., KetelaarsH., BroxtermanH.J., SchefferG., KuiperC.M., TsuruoT., LankelmaJ., MeijerC.J., PinedoH.M.: Distribution of the multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues.Ann. Oncol., 1: 56–64, 1990.
21.
WangL., YangC.P., TrailP., HorwitzS.B., CasazzaA.M.: Reversal of the multidrug resistance (MDR) phenotype with megestrol acetate.Proc. Annu. Meet. Assoc. Cancer Res., 32: A2239, 1991.
22.
WaseemN.H., LaneD.P.: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.J. Cell. Sci., 96: 121–129, 1990.
23.
YatesF.: Analysis of contingency tables with grouping based on quantitative characters.Biometrika, 36: 176–181, 1958.
